化合物简介
Raxatrigine (INN, USAN) (formerly CNV1014802, GSK-1014802) is a novel analgesic under development by Convergence Pharmaceuticals for the treatment of lumbosacral radiculopathy (sciatica) and trigeminal neuralgia (TGN). It acts as a selective, small-molecule, state-dependent Nav1.7 voltage-gated sodium channel blocker. In June 2014, Convergence presented positive results for a phase II clinical study of raxatrigine in the treatment of TGN, including findings that the drug had an excellent efficacy and safety profile and was well-tolerated.[non-primary source needed]
基本信息
中文名称
Raxatrigine
英文名称
(5R)-5-{4-[(2-Fluorobenzyl)oxy]phenyl}-L-prolinamide
中文别名
英文别名
CAS号
934240-30-9
分子式
C18H19FN2O2
分子量
314.354
精确质量
314.143
PSA
65.34
LOGP
4.1616
编号系统
MDL号
MFCD28900694
合成路线
